Scarica l'app Stockscreener
8.08
7.16%
0.54
Dopo l'orario di chiusura:
8.00
-0.08
-0.99%
Precedente Chiudi:
$7.54
Aprire:
$7.54
Volume 24 ore:
1.98M
Relative Volume:
1.00
Capitalizzazione di mercato:
$593.21M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-1.7302
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
+13.80%
1M Prestazione:
+3.06%
6M Prestazione:
-53.19%
1 anno Prestazione:
-68.63%
Intervallo 1D:
$7.52
$8.14
Intervallo di 1 settimana:
$6.955
$8.14
Portata 52W:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
8.08 | 553.57M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Vanguard Group Inc. Buys 1,299,639 Shares of Arvinas, Inc. $ARVN - MarketBeat
What MACD and RSI say about Arvinas Inc.Earnings Overview Summary & Weekly Top Gainers Trade List - Newser
Statistical indicators supporting Arvinas Inc.’s strengthEarnings Recap Report & AI Forecast Swing Trade Picks - Newser
Published on: 2025-08-27 13:32:23 - Newser
What institutional flow reveals about Arvinas Inc.July 2025 Snapshot & Fast Moving Market Watchlists - Newser
What moving averages say about Arvinas Inc.July 2025 Pullbacks & High Accuracy Investment Signals - Newser
Will Arvinas Inc. stock go up soonQuarterly Trade Review & AI Driven Stock Movement Reports - Newser
How high can Arvinas Inc. stock goMarket Rally & Entry Point Confirmation Alerts - Newser
San Francisco investor pressures Arvinas after boosting stake; seeks cost cuts, drug pipeline shift - Hartford Business Journal
T. Rowe Price Investment Management Inc. Has $3.85 Million Stock Holdings in Arvinas, Inc. $ARVN - MarketBeat
Ranking Arvinas Inc. among high performing stocks via toolsMarket Risk Report & Reliable Intraday Trade Alerts - Newser
Arvinas Inc. stock daily chart insightsTrade Signal Summary & Safe Capital Allocation Plans - Newser
Published on: 2025-08-26 17:25:03 - Newser
Technical analysis overview for Arvinas Inc. stockJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - Newser
What Fibonacci levels say about Arvinas Inc. reboundRate Cut & Safe Capital Growth Stock Tips - Newser
Trend analysis for Arvinas Inc. this weekJuly 2025 Sector Moves & Growth Focused Stock Reports - Newser
Applying big data sentiment scoring on Arvinas Inc.Portfolio Gains Summary & Low Risk High Win Rate Picks - Newser
Trendlines Suggest Arvinas Inc. May Bottom Out SoonJuly 2025 PreEarnings & Consistent Growth Equity Picks - beatles.ru
Using data filters to optimize entry into Arvinas Inc.2025 Year in Review & Risk Managed Investment Entry Signals - Newser
Arvinas Inc. Recovers — But Is It SustainableJuly 2025 Analyst Calls & Reliable Price Breakout Signals - beatles.ru
Using economic indicators to assess Arvinas Inc. potentialJuly 2025 Catalysts & Smart Investment Allocation Insights - Newser
Using R and stats models for Arvinas Inc. forecastingShare Buyback & Daily Oversold Bounce Ideas - Newser
What indicators show strength in Arvinas Inc.Bond Market & Weekly High Potential Stock Alerts - Newser
Is Arvinas Inc. Stock a Good Fit for Conservative InvestorsTrade Volume Summary & AI Powered Buy and Sell Recommendations - Newser
Algert Global LLC Buys 257,879 Shares of Arvinas, Inc. $ARVN - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco - MSN
Live Scanner Shows Breakout on Arvinas Inc.July 2025 Reactions & Real-Time Volume Trigger Notifications - 더경남뉴스
Is Arvinas Inc. stock a good dividend stockPortfolio Return Report & Verified Entry Point Detection - theviewers.co.kr
Is Arvinas Inc. building a consolidation baseEarnings Risk Summary & Weekly Watchlist for Consistent Profits - Newser
Arvinas' Surging Institutional Stake and Therapeutic Pipeline Momentum: A High-Conviction Biotech Play - AInvest
Can Arvinas Inc. Rally Enough to Break EvenBond Market & Technical Pattern Based Signals - beatles.ru
Does Arvinas Inc. meet Warren Buffett’s criteriaQuarterly Portfolio Report & Weekly Return Optimization Alerts - theviewers.co.kr
Arvinas' Strategic Crossroads: Logos Global's Aggressive Capital Return Proposal and the Path to Value Realization - AInvest
Logos Global Management Acquires 8.6% Stake in Arvinas, Inc. - AInvest
Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment - MSN
Published on: 2025-08-20 04:59:17 - Newser
Multi asset correlation models including Arvinas Inc.2025 Analyst Calls & Verified Entry Point Detection - Newser
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):